p53-dependent radioresistance in ovarian carcinoma cell lines

Cancer Letters

Volumn 150, Issue 2, 2000, Pages 191-199

  Concin, Nicole ^a   Zeillinger, Christa ^a   Stimpfel, Margit ^a   Schiebel, Ingrid ^a   Tong, Dan ^a   Wolff, Uwe ^b   Reiner, Angelika ^d   Leodolter, Sepp ^a,c   Zeillinger, Robert ^a  

^a UNIVERSITY OF VIENNA   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c LUDWIG BOLTZMANN INSTITUTE FOR LUNG VASCULAR RESEARCH   (Austria)

^d Donauspital ^*  (Austria)

Author keywords

Bcl 2; Growth rate; Ovarian cancer; p53; Radioresponsiveness

Indexed keywords

ADENOSINE TRIPHOSPHATE; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN BCL 2; PROTEIN P53;

ARTICLE; CANCER CELL CULTURE; CANCER RADIOTHERAPY; CONTROLLED STUDY; CYTOTOXICITY; DOSE RESPONSE; FEMALE; FLOW CYTOMETRY; GROWTH RATE; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; OVARY CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIOSENSITIVITY; TUMOR SUPPRESSOR GENE;

DOSE-RESPONSE RELATIONSHIP, RADIATION; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; OVARIAN NEOPLASMS; PROTO-ONCOGENE PROTEINS C-BCL-2; RADIATION TOLERANCE; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0034001247     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3835(99)00393-6     Document Type: Article

References (31)

1. Lanciano R., Reddy S., Corn B., Randall M. Update on the role of radiotherapy in ovarian cancer. Semin. Oncol. 25:1998;361-371.
2. Eliopoulos A.G., Kerr D.J., Herod J., Hodgkins L., Krajewski S., Reed J.C., Young L.S. The control of apoptosis and drug resistance in ovarian cancer: influence of p53 and bcl-2. Oncogene. 11:1995;1217-1228.
3. Hockenbery D., Nunez G., Milliman C., Schreiber R.D., Korsmeyer S.J. Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature. 348:1990;334.
4. Amundson S.A., Myers T.G., Fornace A.J. Roles for p53 in growth arrest and apoptosis: putting on the brakes after genotoxic stress. Oncogene. 17:1998;3287-3299.
5. Zambetti G.P., Bargonetti J., Walker J. Wild-type p53 mediates positive regulation of gene expression through a specific DNA sequence element. Genes Dev. 6:1992;1143-1152.
6. Kastan M.B., Onyekwere O., Sidransky D., Vogelstein B., Craig R.W. Participation of p53 protein in cellular response to DNA damage. Cancer Res. 51:1991;6304-6311.
7. Lane D.P. p53, guardian of the genome. Nature. 258:1992;15-16.
8. Lowe S.W., Ruley H.E., Jacks T., Housman D.E. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell. 74:1993;957-967.
9. Gallion H.H., Pieretti M., DePriest P.D., van Nagell J.R. The molecular basis of ovarian cancer. Cancer. 76:1995;1992-1997.
10. Bliade S., Stobbe C.C., Chapman J.D. The intrinsic radiosensitivity of some human tumor cells throughout their cell cycles. Radiat. Res. 147:1997;416-421.
11. Sevin B.U., Peng Z.L., Perras J.P., Ganjei P., Penalver M., Averette H.E. Application of an ATP-bioluminescence assay in human tumor chemosensitivity testing. Gynecol. Oncol. 31:1988;191-204.
12. Kohler M.F., Kerns B.J., Humphrey P.A., Marks J.R., Bast R.C., Berchuck A. Mutation and overexpression of p53 in early-stage epithelial ovarian cancer. Obstet. Gynecol. 81:1993;643-650.
13. Vojtesek B., Bartek J., Midgley A., Lane D.P. An immunochemical analysis of the human nuclear phosphoprotein p53: new monoclonal antibodies and epitope mapping using recombinant p53. J. Immunol. Methods. 151:1992;237-244.
14. Hsu S., Raine I., Fanger H. The use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase technique-A comparison between ABC and unlabeled antibody (PAP) procedures. J. Histochem. Cytochem. 29:1981;577-580.
15. Flaman J.M., Frebourg T., Moreau V., Charbonnier F., Martin C., Chappuis P., Sappino A.P., Limacher J.M., Bron I., Benhattar J., Tada M., Van Meir E.G., Estreicher A., Iggo R.D. A simple p53 functional assay for screening cell lines, blood, and tumors. Proc. Natl. Acad. Sci. USA. 92:1995;3963-3967.
16. Gallardo D., Drazan K.E., McBride W.H. Adenovirus-based transfer of wild type p53 gene increases ovarian tumor radiosensitivity. Cancer Res. 56:1996;4891-4893.
17. Pestell K.E., Medlow C.J., Titley J.C., Kelland L.R., Walton M.I. Characterisation of the p53 status. BCL-2 expression and radiation and platinium drug sensitivity of a panel of human ovarian cancer cell lines. Int. J. Cancer. 77:1998;913-918.
18. Brown R., Clugston C., Burns P., Edlin A., Vasey P., Vojtesek B., Kaye S.B. Increased accumulation of p53 protein in cisplatin-resistant ovarian cell lines. Int. J. Cancer. 55:1993;678-684.
19. Perego P., Giarola M., Righetti S.C., Supino R., Caserini C., Delia D., Pierotti M.A., Miyashita T., Reed J.C., Zunino F. Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian cancer cell systems. Cancer Res. 56:1996;556-562.
20. Herod J.J., Eliopoulos A.G., Warwick J., Niedobitek G., Young L.S., Kerr D.J. The prognostic significance of Bcl-2 and p53 expression in ovarian carcinoma. Cancer Res. 56:1996;2178-2184.
21. Petru E., Sevin B.U., Gottlieb C.H. Radiosensitivity patterns of four human ovarian cancer cell lines in vitro. Gynecol. Oncol. 64:1997;490-492.
22. Weisenthal L.M., Lippman M.E. Clonogenic and nonclonogenic in vitro chemosensitivity assays. Cancer Treat. Rep. 69:1985;615-632.
23. Bertoncello I., Bradley T.R., Campbell J.J., McDonald I.E., McLeish G.R., Quin M.A., Rome R., Hodgson G.S. Limitations of the clonal agar assay for assessement of primary human ovarian tumor biopsies. Br. J. Cancer. 45:1982;803-811.
24. Nguyen H.N., Sevin B.U., Averette H.E., Gottlieb C.F., Perras J., Ramos R., Donato D., Penalver M. The use of ATP bioluminescence assay and flow cytometry in predicting radiosensitivity of uterine cancer cell lines: correlation of radiotoxicity and cell cycle kinetics. Gynecol. Oncol. 46:1992;88-96.
25. Kangas I., Gronroos M., Nieminen A.L. Bioluminescence of cellular ATP: a new method for evaluating cytotoxic agents in vitro. Med. Biol. 62:1984;338-343.
26. Rodriguez M., Sevin B.U., Perras I.P., Nyugen H.N., Koechli O.R., Sklar M.D. Mammalian cell line radiation dose response curves correlate when evaluated by clonogenic assay and adenosine triphosphate cell viability assay. Proc. Am. Cancer Res. 1993;000.
27. Hall P.A., Ray A., Lemoin N.R., Midgley C.A., Krausz T., Lane D.P. p53 immunostaining as a marker of malignant disease in diagnostic cytopathology. Lancet. 338:1991;513.
28. Bartek J., Bartkova J., Vojtesek B., Staskova Z., Lukas J., Rejthar A., Kovarik J., Midgley C.A., Gannon J.V., Lane D.P. Aberrant expression of the p53 oncoprotein is a common feature of a wide spectrum of human malignancies. Oncogene. 6:1991;1699-1703.
29. Yaginuma Y., Westphal H. Abnormal structure and expression of the p53 gene in human ovarion carcinoma cell lines. Cancer Res. 52:1992;4196-4199.
30. Midgley C.A., Lane D.P. p53 protein stability in tumor cells is not determined by mutation but is dependent on Mdm2 binding. Oncogene. 15:1997;1179-1189.
31. Mihara K., Miyazaki M., Kondo T., Fushimi K., Tsuji T., Inoue Y., Fukaya K., Ishioka C., Namba M. Yeast funktional assay of the p53 gene status in human cell lines maintainted in our laboratory. Acta Med. Okayama. 51:1997;261-265.